Pharvaris Presents Phase 3 Deucrictibant Data at ACAAI Meeting
Pharvaris presented Phase 3 deucrictibant data at the ACAAI Annual Scientific Meeting.
Related stories
Amazon Shares Fall 7.21% After Hours
Amazon shares fell 7.21% in after-hours trading.
M impact | EQUITY | Oct 30, 2026, 07:25 AM UTC
Ueda Says Trading Volume Fell Short of Assumption in BOJ ETF Sales Decision
BOJ Governor Kazuo Ueda said market trading volume increased, while actual volume was below the level initially assumed in the decision to accelerate ETF sales.
M impact | EQUITY | Oct 30, 2026, 07:24 AM UTC
Sylvania Platinum Q1 Revenue Rises 30% on Record PGM Output
Sylvania Platinum reported a 30% rise in Q1 revenue alongside record PGM output.
M impact | EQUITY | Oct 30, 2026, 07:24 AM UTC
Alphabet shares plunge 12.6% amid AI profitability doubts
Alphabet shares fell 12.6%; the report cites doubts about AI profitability.
H impact | EQUITY | Oct 30, 2026, 07:24 AM UTC
Japan’s Nikkei Falls 2.1% as AI Spending Concerns Hit Tech Shares
The Nikkei fell as much as 3% before closing down 2.1%, with chip-related shares leading losses amid concerns about the sustainability of spending supporting the AI boom.
M impact | EQUITY | Oct 30, 2026, 07:22 AM UTC
BP Tops Q3 Profit Expectations on Higher Refining Margins and Trading
H impact | EQUITY | Oct 30, 2026, 07:17 AM UTC